Author

James Butler 1

1 AbbVie Inc.,North Chicago,United States

A HIGHER INDUCTION DOSING REGIMEN OF ADALIMUMAB DOES NOT ENHANCE MODULATION OF DOWNSTREAM BLOOD MOLECULAR MARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE OR ULCERATIVE COLITIS: RESULTS FROM THE SERENE-CD AND SERENE-UC STUDIES

Marc Ferrante, Valerie Pivorunas, James Butler, Naim Mahi, Nael M. Mostafa, Melanie Ruzek, James Fann, Feng Hong, Xiaohong Cao, Nizar Smaoui, Justin Wade Davis, Jasmina Kalabic, Alexandra Song, Heath M. Guay, Florian Rieder, Julian Panés, Jean-Frédéric Colombel

CONCORDANCE OF STOOL FREQUENCY AND ABDOMINAL PAIN MEASURES WITH SIMPLE ENDOSCOPIC SCORE FOR CROHN'S DISEASE

James D Lewis, Paul Rutgeerts, Geert R. D'Haens, Jean-Frederic Colombel, William Sandborn, Walter Reinisch, James Butler, Jen Fue Maa, Anne M. Robinson

MECHANISMS OF NON-RESPONSE TO ADALIMUMAB IN INFLAMMATORY BOWEL DISEASE: PERIPHERAL PROTEOMIC AND TRANSCRIPTOMIC PROFILING FROM THE SERENE-CD AND SERENE-UC STUDIES

Julian Panés, Bram Verstockt, Valerie Pivorunas, James Butler, Naim Mahi, Melanie Ruzek, Thierry Sornasse, James Fann, Feng Hong, Xiaohong Cao, Nizar Smaoui, Justin Wade Davis, Jasmina Kalabic, Alexandra Song, Heath M. Guay, Azucena Salas, Nick Kennedy, Tariq Ahmad, Severine Vermeire

Item 1 - 3 / 3
1